Home | Medical-Newswire.Com:
(Medical-NewsWire.com, September 20, 2012 ) New York, NY -- Advanced Medical Isotope Corporation (ADMD) is already a US-based manufacturer and distributor of medical isotopes and is also developing key technologies that may offer a superior alternative to the current standard of care for battling cancer with nuclear medicine.
In a Thursday report, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies key point for optimism regarding the company and examines its speculative potential as an investment. Full report available at: http://vfcsstockhouse.com/blog/article/-advanced-medical-isotope-corporation-expanded-distribution-and-radiogel-technology-hold-the-keys-to-the-future
Advanced Medical Isotope Corporation (ADMD) has - through key partnerships, expanding distribution channels and the acquisition of a license to a novel cancer-fighting technology - well positioned itself to become a growth player in the field of nuclear medicine, specifically in the field of the production and distribution of medical isotopes. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases and are deemed a hot item whenever discussed because of the geopolitical implications of non-nuclear nations attempt to enrich uranium for - ahem - solely medical purposes.
Advanced Medical is one of only a few companies in the United States manufacturing and distributing such isotopes and it's likely that business could quickly hit a growth spurt - not only through the company's own indigenous expansion and distribution efforts, but also because of the growing desire of the medical community in the US to use 'home grown' nuclear materials, not to mention increasing regulation that may force the community to do so anyway.
AMIC already offers a broad variety of isotopes and, as outlined in a recent quarterly report, is looking to expand its 'pipeline' of product offerings for its distribution network of customers that include - but is not limited to - national laboratories, hospitals, research facilities and universities.
Many of the company's isotopes are put to use through molecular imaging, or Positron Emission Tomography (PET), which enables Doctors and medical professionals to identify cancerous condictions well before detection means that search for tumor mass. Some of the radiopharmaceutical products based on the medical isotopes are also used in the early detection of certain cardiovascular indications and, as mentioned above, the demand for such products is growing, not shrinking. According to numbers identified in a recent company presentation and credited to the World Nuclear Association, the use of medical isotopes is growing at an annual rate of 10%.
That places AMIC right in the middle of a potential growth boom.
While production and distribution may encompass the company's core business model, AMIC is moving heavily into the field of treatment, too. The process of placing radioactive "seeds" in or near a cancerous tumor is known as brachytherapy, and AMIC is developing a pipeline based on such technology to augment the already-growing core business plan.
In April, the company acquired a license and numerous relating patents to an injectible radiogel technology that could have a significant impact on the next generation of fighting cancer. Using the radiogel technology doctors could deliver Yttrium-90 "microspheres" directly into cancerous tissue. Because the injectible polymer turns solid and holds the microspheres in place, there is little to no threat of any radiation escaping and damaging surrounding tissue. As described by Dr. Alan Walter, Chair of the AMIC Scientific Committee, in a presentation available on the company's home page, such a technology could be termed as using "smart bullets" to target cancerous cells.
Yttrium-90, in the form of Polymer seeds, is an already-established medical isotope with numerous applications in existing cancer treatment and has demonstrated effectiveness in combating head, neck, liver and prostate cancers, according to an above-linked company presentation. The radiogel application of Yttrium-90 could potentially 'storm the scene' in treating numerous cancer types with the intent of targeting those tumors in the hard-to-get to areas of the body that eliminates surgery as an option.
Both the Polymer seeds and the acquired the radiogel technology significantly boost the diversity of AMIC, offering a targeted path to enter the realm of caner treatment to augment the production, sales and distribution channels of its isotopes.
It's possible, based on previous expectations, that the Brachytherapy pipeline could hit market within a couple of years. At that point AMIC could either move forward with commercialization on its own or out-license the technology to someone else and use that revenue stream of royalties to fund the expansion of the core business.
Shares were up by eight percent on Wednesday, although volume was very light. That said, volume has been picking up significantly over the past few months and has tripled already once this year. Volume has also stormed in after the company's more relevant press releases, indicating that there are investors on the sidelines who either wait to play a quick trade or may be taking a 'wait and see' approach to playing this still-speculative stock.
Should the potential of the AMIC distribution network continue to expand and meet the growing demand for nuclear medicine - and should the polymer seeds and radiogel technology also hit market with momentum - then it's likely that the current ADMD share price could start to move. Currently, shares consistently trade for a few pennies above the twenty cents mark, give or take.
Based on the potential of the developing technology, already-available products and future product offerings, the current ADMD trading levels could serve as an opportune accumulation period to those looking at the risk/reward profile for the future. The current market cap of still under twenty million indicates that many investors are still unconvinced, but when searching for potential payoff picks on the bulletin board stocks, it pays off to be in while the stock is still moving along relatively unnoticed, as the best percentage gains to be had in any run start with being in place before the run starts.
That said, the stock market is risky business and there are no sure things, that's why it's up to each investor to conduct his or her own DD and invest accordingly.
Still a developing story worth monitoring.
Disclosure: No position.
Follow ADMD developments and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: email@example.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights and opinions into broader-market news. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and make informed and well thought-out investment decisions. For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Amgen scraps trials of drug for advanced stomach cancer
24 Nov 2014 at 6:34am
(Reuters) - Amgen Inc on Monday said it will scrap all trials of its experimental treatment rilotumumab in patients with advanced stomach cancer, after a safety monitoring board associated it with a higher incidence of deaths. The world's largest biotechnology company said the independent safety board found that patients taking both the drug and chemotherapy had an increased number of deaths than those taking chemotherapy alone. Company officials could not immediately be reached for additional details. (Reporting by Ransdell Pierson Editing by W Simon)
Bird flu is major threat to poultry along migration routes: FAO/OIE
24 Nov 2014 at 6:30am
PARIS (Reuters) - A bird flu strain found in Europe represents a major threat to the poultry industry in countries crossed by migrating wild birds, two intergovernmental organizations said on Monday. Germany, the Netherlands and Britain have reported cases this month of the H5N8 highly pathogenic bird flu, which is similar to one that devastated poultry flocks in South Korea earlier this year, but has never been detected in humans. ...
Germany orders some poultry kept inside to protect against bird flu
24 Nov 2014 at 6:19am
By Michael Hogan HAMBURG (Reuters) - Farm poultry in German regions with a high risk of contact with migrating wild birds must be kept inside farm buildings to protect against the risk of contracting bird flu, German authorities said on Monday. The decision was taken by federal and state authorities after case of bird flu was found in a wild duck on Saturday, the state government of North Rhine Westfalia said in a statement. The first case of H5N8 bird flu in Germany was confirmed on Nov. 4 on a poultry farm in Mecklenburg-Vorpommern in east Germany. ...
Merck buys rights to NewLink's experimental Ebola vaccine
24 Nov 2014 at 7:39am
By Ransdell Pierson (Reuters) - Merck & Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Large late-stage trials of the product could begin early next year, Merck said. Merck, the No. 2 U.S. drugmaker and one of the world's biggest makers of vaccines, would be able to speed up and significantly boost production of the product. The Public Health Agency of Canada, which originally developed the rVSV-EBOV vaccine, will retain non-commercial rights. ...
EXCLUSIVE: Pay per puff? Caffeine stick? E-cigarette boom sparks race for new...
24 Nov 2014 at 6:10am
By Martinne Geller and Ben Hirschler LONDON (Reuters) - Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices. ...
Merry marijuana: Pot sellers woo holiday shoppers
24 Nov 2014 at 6:09am
DENVER (AP) ? That's not mistletoe.
Workout Classes You Can Stream From Home
24 Nov 2014 at 6:03am
Life is busy. Life is hard. Life is too short to drive all over town just to exercise. When you need to squeeze in a quick workout, stream it straight from your laptop. Here are some of the best fitness options on the web.FITFUSIONMeet your new best friend, FitFusion. It's basically Netflix for workouts. Cheaper than a single green juice ($6 a...
Italian doctor with Ebola returning for treatment
24 Nov 2014 at 5:32am
MILAN (AP) ? An Italian doctor who has been working in Sierra Leone has tested positive for the Ebola virus and is being transferred to Rome for treatment, the health ministry said Monday. It is Italy's first confirmed case of Ebola.
Liberia free of Ebola by Christmas, says president
24 Nov 2014 at 5:22am
MONROVIA, Liberia (AP) ? Liberia's president on Monday urged her countrymen to double their efforts to reach the government's goal of having zero new Ebola cases by Dec. 25, a target some experts have described as highly ambitious.
"Avoid stigmatising Africa," musician says as West Africa Ebola song launched
24 Nov 2014 at 4:43am
By Misha Hussain DAKAR (Thomson Reuters Foundation) - Some of Africa's top musicians launched on Monday an alternative Ebola appeal song to Band Aid's new recording of "Do they know it's Christmas' with proceeds also going to fight the virus that has killed more than 5,000 people in West Africa this year. ...
BioMarin to buy Prosensa in $840 million deal
24 Nov 2014 at 4:40am
(Reuters) - BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million including milestone payments, aiming to add to its portfolio of drugs to treat rare diseases.
Italian Ebola patient due to be flown home: health ministry
24 Nov 2014 at 3:48am
ROME (Reuters) - An Italian doctor who contracted Ebola while working in Sierra Leone is being flown to Italy, the Health Ministry in Rome said on Monday. The ministry said the doctor, who had been working for the humanitarian group Emergency, was in a stable condition and was eating and drinking on his own. He is expected to arrive on Monday night and will be treated in the Lazzaro Spallanzani infectious diseases institute in Rome, the ministry said.
U.S. seeks to step up India trade talks after WTO breakthrough
24 Nov 2014 at 3:45am
NEW DELHI (Reuters) - The United States wants to step up its trade dialogue with India, Trade Representative Michael Froman said on Monday, after the resolution of a global trade dispute paved the way for President Barack Obama to visit India. Direct contacts between Obama and Prime Minister Narendra Modi this month helped to end a deadlock that had prevented the World Trade Organization from implementing a $1 trillion package of reforms to global customs rules. ...
Court case pushed by think tank could leave uninsured out in the cold
24 Nov 2014 at 2:00am
Supreme Court case backed by think tank hinges on single sentence in Affordable Care Act.
GSK shareholders to vote on Novartis deal on Dec. 18
24 Nov 2014 at 12:51am
LONDON (Reuters) - Britain's GlaxoSmithKline has asked its shareholders to vote at a meeting on Dec. 18 on its proposed major deal with Switzerland's Novartis , which will see the two pharmaceutical group trade more than $20 billion of assets. The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer healthcare, was unveiled in April. ...